Miller Anestesia

63. Eng J, Kay PH, Murday AJ, et al: Post-operative

autologous transfusion in cardiac surgery: A pros-

pective, randomized study. Eur J Cardiothorac Surg

4:595, 1990.

64. Semkiw LB, Schurman OJ, Goodman SB, et al:

Postoperative blood salvage using the cell saver

after total joint arthroplasty. J Bone Joint Surg Am

71:823, 1989.

65. Martin JW, Whiteside LA, MillianoMT, et al: Posto-

perative blood retrieval and transfusion in

cementless total knee arthroplasty. J Arthroplasty

7:205, 1992.

66. Umlas J, Foster RR, Dalal SA, et al: Red cell loss

following orthopedic surgery: The case against

postoperative blood salvage. Transfusion 34:402,

1994.

67. Ritter MA, Keating EM, Faris PM: Closed wound

drainage in total hip or knee replacement: A pros-

pective, randomized study. J Bone Joint Surg Am

76:35, 1994.

68. Clements DH, Sculco TP, Burke SW, et al: Salvage

and reinfusion of postoperative sanguineous wound

drainage. J Bone Joint Surg Am 74:646, 1992.

69. Woda R, Tetzlaff JE: Upper airway oedema follo-

wing autologous blood transfusion from a wound

drainage system. Can J Anesth 39:290, 1992.

70. Blevins FT, Shaw B, Valeri RC, et al: Reinfusion of

shed blood after orthopaedic procedures in chil-

dren and adolescents. J Bone Joint Surg Am 75:363,

1993.

71. Goodnough LT, Verbrugge D, Marcus RE: The

relationship between hematocrit, blood lost, and

blood transfused in total knee replacement: Impli-

cations for postoperative blood salvage and reinfu-

sion. Am J Knee Surg 8:83, 1995.

72. Baker JW, Spotnitz WD, Matthew TL, et al: Medias-

tinal fibrin glue: Hemostatic effect and tissue res-

ponse in calves. Ann Thorac Surg 47:450, 1989.

73. Silberstein LE, Williams LJ, Hughlett MA, et al: An

autologous fibrinogen-based adhesive for use in

otologic surgery. Transfusion 28:319, 1988.

74. Gibble JW, Ness PM: Fibrin glue: The perfect ope-

rative sealant? Transfusion 30:741, 1990.

75. Milde LN: An anaphylactic reaction to fibrin glue.

Anesth Analg 679:684, 1989.

76. Wilson SM, Pell P, Donegan EA: HIV-1 transmis-

sion following the use of cryoprecipitated fibrino-

gen as gel/adhesive [abstract]. Transfusion 31:51S,

1991.

77. Burnouf-Radosevich M, Burnouf T, Huart JJ: Bio-

chemical and physical properties of a solvent-deter-

gent-treated fibrin glue. Vox Sang 58:77, 1990.

78. Banninger H, Hardegger T, Tobler A, et al: Fibrin glue

in surgery: Frequent development of inhibitors of

bovine thrombin and human factor V. Br J Haematol

85:528, 1993.

79. Hedner U, Erhardtsen E: Potential role for rFVIIa

in transfusion medicine. Transfusion 42:114, 2002.

80. Goodnough LT: Experience with recombinant

factor VIIa in thrombocytopenic patients. Semin

Hematol 41(Suppl 1):25, 2003.

81. Poon MC, Demers C, Jobin F, Wu JW: Recombinant

factor VIIa is effective for bleeding and surgery in

patients with Glanzmann thrombasthenia. Blood

94:3591, 1999.

82. Goodnough LT. Treatment of bleeding in the inten-

sive care unit. In Goodnough LT (guest ed): Recom-

binant factor VIIa: Potential treatment of critical

bleeding in the future ICU. Int Care Med 28A5,

2002.

83. Martinowitz U, Kenet G, Segale N, et al: Recombi-

nant activated factor VII in adjunctive hemorrhage

control in trauma. J Trauma 51:431, 2001.

84. Levy M, Peters M, Buller HR: Efficacy and safety of

recombinant factor VIIa for treatment of severe

bleeding. Crit Care Med 33:883, 2005.

85. Goodnough LT, Lublin DM, Zhang L, et al: Trans-

fusion medicine service policies for recombinant

factor VIIa administration. Transfusion 44:1325,

2004.

86. Park P, Fewel ME, Garton HJ, et al: Recombinant

activated factor VII for the rapid correction of

coagulopathy in nonhemophiliac neurosurgical

patients. Neurosurgery 53:34, 2003.

87. Friederich PW, Henny CP, Messelink EJ, et al: Effect

of recombinant activated factor VII on periopera-

tive blood loss in patients undergoing retropubic

prostatectomy: A double-blind, placebo-controlled

randomized trial. Lancet 361:201, 2003.

88. Karkouti K, Beattie WC, Wijeysundera, et al:

Recombinant factor VIIa for intractable blood loss

after cardiac surgery. Transfusion 45:26, 2005.

89. Karkouti K, Yau TM, Riazi S, et al: Determinants of

complications with recombinant factor VIIa for

refractory blood loss in cardiac surgery. Can J

Anaesth 53:802, 2006.

90. McCall P, Story DA, Karapillai D: Audit of factor

VIIa for bleeding resistant to conventional therapy

following complex cardiac surgery. Can J Anaesth

53:926, 2006.

91. Von Heyman C, Redlich U, Jain U, et al: Recombi-

nant activated factor VII for refractory bleeding

after cardiac surgery. Crit Care Med 33:2241, 2005.

92. Diprose P, Herbertson MJ, O’Shaughnessy D, Gill

RS: Activated recombinant factor VII after cardio-

pulmonary bypass reduces allogeneic transfusion in

complex non-coronary cardiac surgery: Randomi-

zed double-blind placebo-controlled pilot study. Br

J Anaesth 95:596, 2005.

93. Ekert H, Brizard C, Eyers R, et al: Elective adminis-

tration in infants of low-dose recombinant activa-

ted factor VII (rFVIIa) in cardiopulmonary bypass

surgery for congenital heart disease does not

shorten time to chest closure or reduce blood loss

and need for transfusions: A randomized, double-

blind, parallel group, placebo-controlled study of

rFVIIa and standard haemostatic replacement

therapy versus standard haemostatic replacement

therapy. Blood Coag Fibrin 17:389, 2006.

94. Boffard KD, Riou B, Warren B, et al: Adjunctive

therapy for bleeding control in severely injured

trauma patients. J Trauma 59:8, 2005.

95. O’Connell NM, Perry DJ, Hodgson AJ, et al: Recom-

binant fVIIa in the management of uncontrolled

hemorrhage. Transfusion 43:1711, 2003.

96. Deveras RAE, Kessler CM: Recombinant factor VIIa

(rFVIIa) successfully and rapidly corrects the exces-

sively high international normalized ratio (INR)

and prothrombin times induced by warfarin. Blood

96:638a, 2000.

97. Deveras RA, Kessler CM: Reversal of warfarin-

induced excessive anticoagulation with recombi-

nant human factor VIIa concentrate. Ann Intern

Med 137:884, 2002.

98. Lin J, Hanigan WC, Tarantino M, Wang J: The use

of recombinant activated factor VII to reverse war-

farin-induced anticoagulation in patients with

hemorrhages in the central nervous system: Preli-

minary findings. J Neurosurg 98:737, 2003.

99. Brody DL, Aiyagari V, Shackleford AM, Diringer

MN: Use of recombinant factor VIIa in patients

with warfarin-associated intracranial hemorrhage.

Neurocrit Care 2:263, 2005.

100. Shao YF, Yang YM, Chau GY, et al: Safety and

hemostatic effect of recombinant activated factor

VII in cirrhotic patients undergoing partial

hepatectomy: A multicenter, randomized, double-

blind placebo-controlled trial. Am J Surg 191:245,

2006.

101. Lodge JP, Jonas S, Jones RM, et al: Efficacy and safety

of repeated perioperative doses of recombinant

factor VIIa in liver transplantation. Liver Transpl

11:973, 2005.

102. Jeffers L, Chalasani N, Balart L, et al: Safety and

efficacy of recombinant factor VIIa in patients with

liver disease undergoing laparoscopic liver biopsy.

Gastroenterology 123:118, 2002.

103. Bosch J, Thabut D, Bendtsen F, et al: Recombinant

factor VIIa for upper gastrointestinal bleeding in

patients with cirrhosis: A randomized double-blind

trial. Gastroenterology 127:1123, 2004.

104. Mannucci PM, Levi M: Drug therapy: Prevention

and treatment of major blood loss. N Eng J Med

356:2301, 2007.

105. Lodge JPA, Jonas S, Malago M, et al: Recombinant

coagulation factor VIIa in major liver resection.

Anesthesiology 102:269, 2005.

106. Mayer SA, Brun NL, Begtrup K, et al: Recombinant

activated factor VII for acute intracerebral hemo-

rrhage. N Engl J Med 352:777, 2005.

107. O’Connell NM: Factor XI deficiency—from mole-

cular genetics to clinical management. Blood Coag

Fibrin 14(Suppl 1):S59, 2003.

108. Pickard JD, Kirkpatrick PJ, Melsen T, et al: Potential

role of NovoSeven in the prevention of rebleeding

following aneurismal subarachnoid haemorrhage.

Blood Coagul Fibrinolysis 11(Suppl 1):S117, 2000.

109. Laffan M, O’Connell NM, Perry DJ, et al: Analysis

and results of the recombinant factor VIIa extended

use registry. Blood Coagul Fibrinolysis 14(Suppl

1):S35, 2003.

110. O’Connell KA, Wood SS, Wise RP, et al: Thromboe-

mbolic adverse events after use of recombinant

human coagulation factor VIIa. JAMA 295:293,

2006.

111. Levy J, Fingerhut A, Brott T, et al: Recombinant

factor VIIa in patients with coagulopathy: Review

of safety. Transfusion 46:919, 2006.

112. Warren O, Mandel K, Hadjianastassiou V, et al:

Recombinant activated factor VII in cardiacsurgery:

A systematic review. Ann Thorac Surg 83:707,

2007.

113. Bui JD, Despotis GD, Trulock EP, et al: Fatal throm-

bosis after administration of activated prothrombin

complex concentrates in a patient supported by

extracorporeal membrane oxygenation who had

received activated recombinant factor VII. J Thorac

Cardiovasc Surg 124:852, 2002.

114. Shander A, Goodnough LT, Ratko T, et al: Consen-

sus recommendations for the off-label use of

recombinant human factor VIIa (NovoSeven)

therapy. Pharmacol Ther 30:644, 2005.

115. Matthew P, Simon TL, Hunt KE, Crookston KP:

How we manage requests for recombinant factor

VIIa. Transfusion 47:8, 2007.

116. Rosencrantz D, Shander A, Ozawa S, Spence RK:

Establishing a bloodless medicine and surgery

center.

Transfusion Medicine and Alternatives to

Blood Transfusion. R J Editions Medicales, 2000.

117. Kickler TS: Why “bloodless medicine” and how

should we do it? Transfusion 43:550, 2003.

118. Goodnough LT, Shander AS: Blood management.

Arch Pathol Lab Med 35:167, 2007.

Autotransfusión, factor VIIa recombinante y medicina sin transfusiones

1559

Sección III

Control de la anestesia